Urban ePRO
0+
Downloads
Everyone
info
About this app
The study will evaluate the efficacy and safety of obinutuzumab in patients with advanced non-pretreated follicular lymphoma (LF) undergoing treatment with obinutuzumab as part of routine clinical practice, measured by the percentage of patients who relapsed in 24 months following the start of treatment (POD24).
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
This app may collect these data types
Personal info
Data is encrypted in transit
Data can’t be deleted
App support
phone
Phone number
+390223992999
About the developer
ADVICE PHARMA GROUP SRL
developer.advice@advicepharma.com
VIA OLGETTINA 60
20132 MILANO
Italy
+39 340 586 2032